Trial · NCT05031780
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 40
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 2: Percentage of Participants With Hemoglobin (Hb) Response | Week 12 | |
| Primary | Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs) | Up to Week 12 | |
| Primary | Phase 3: Percentage of Participants With Hb Response | Week 52 | |
| Primary | Phase 3: Annualized Rate of Sickle Cell Pain Crises (SCPCs) | Up to Week 52 | |
| Secondary | Phase 2: Change From Baseline in Hb Concentration | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Change From Baseline in Indirect Bilirubin | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Change From Baseline in Lactate Dehydrogenase (LDH) | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Change From Baseline in Absolute Reticulocytes Count | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Change From Baseline in Percent Reticulocytes | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Change From Baseline in Erythropoietin | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Change From Baseline in Patient-Reported Outcomes Measurement Information System® (PROMIS®) Fatigue 13a Short Form (SF) Score | Baseline, Week 10 up to Week 12 | |
| Secondary | Phase 2: Annualized Rate of SCPCs | Up to Week 12 | |
| Secondary | Phase 2: Pharmacokinetic/Pharmacodynamic Relationship: Evaluate the Exposure of Mitapivat to the Change in Adenosine Triphosphate (ATP) and 2,3-Diphosphoglycerate (2,3-DPG) | Day 1 up to Week 8 | |
| Secondary | Phase 2: Mitapivat Concentration Over Time | Day 1 up to Week 8 | |
| Secondary | Phase 2: Mitapivat Area Under the Concentration | Day 1 up to Week 8 | |
| Secondary | Phase 2: Mitapivat Maximum (Peak) Concentration | Day 1 up to Week 8 | |
| Secondary | Phase 3: Change From Baseline in Hb Concentration | Baseline, Week 24 up to Week 52 | |
| Secondary | Phase 3: Change From Baseline in Indirect Bilirubin | Baseline, Week 24 up to Week 52 | |
| Secondary | Phase 3: Change From Baseline in Percent Reticulocytes | Baseline, Week 24 up to Week 52 | |
| Secondary | Phase 3: Change From Baseline in PROMIS® Fatigue 13a SF Scores | Baseline, Week 24 up to Week 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05031780/registered